Elevated plasma lactate level associated with high dose inhaled albuterol therapy in acute severe asthma

G J Rodrigo, C Rodrigo

Background: Lactic acidosis is a recognised event in adult patients with status asthmaticus, particularly in the setting of intensive care. However, it has been infrequently studied in patients attending the emergency departments (ED).

Methods: We conducted a prospective and descriptive study to assess levels of lactate and effects on bronchodilator response in adult patients with acute severe asthma treated with high doses of albuterol in the ED. In total, 18 subjects (mean (SD) age 42.9 (2.7) years, FEV1 = 32.2 (10.9)% of predicted) who presented to an emergency department were enrolled in the study. All patients were treated with albuterol; four puffs (100 µg/puff) at 10 minute intervals, delivered by a pressurised metered dose inhaler into a spacer device over a 2 hour period.

Results: At the end of treatment, mean (SD) plasma lactate level (2.94 (2.1) mmol/l) was significantly higher (p = 0.001) than baseline. Of the 18 patients, nine (50%) showed lactate levels ≥2.5 mmol/l (four patients presented values >4 mmol/l); these patients had a shorter duration of attack prior to ED presentation (p = 0.01), a higher pretreatment heart rate (p = 0.005), a lower pretreatment SP02 (p = 0.03), a lower pretreatment PO2 (p = 0.009), a higher pretreatment PICO2, and a lower pretreatment serum potassium (p = 0.005). However, there were no significant differences in the airway response between groups.

Conclusions: This study confirmed previous observations that high lactate concentrations can develop during the first hours of inhaled beta agonist treatment. The presence of a previous hyperadrenergic state may predispose to the development of this condition. A significant improvement in lung function was associated with elevated lactate levels.

Methods

Subjects
We studied all adult patients with acute asthma who were seen in the ED of the Hospital Central de las Fuerzas Armadas in Montevideo, Uruguay, over a 3 month period (March–May 2003). The inclusion criteria for patients were: (a) diagnosis of asthma based on the criteria of the Global Initiative for Asthma,14 (b) age between 18 and 50 years and (c) a forced expiratory volume in 1 second (FEV1) <50% of predicted value. Patients were excluded if they had: (a) a temperature >38°C or (b) a history of cardiac, hepatic, renal, or other disease, or were pregnant. Patients who expressed willingness to participate in the study gave their written informed consent, and the hospital ethics committee approved the study.

Protocol
After initial assessment, all patients were treated with albuterol, four puffs for each dose, delivered at 10 minute intervals by a pressurised metered dose inhaler into a spacer device (Volumatic; Allen & Hansbury Ltd, UK). As each puff (100 µg) was delivered into the spacer, the patient performed a deep inhalation from the spacer. The protocol involved 120 minutes of this treatment (1200 µg of albuterol every 30 minutes). After this time, all patients with a poor response (FEV1 <50% of predicted) received intravenous hydrocortisone 500 mg. The protocol included the administration of O2.

Abbreviations: ED, emergency department
Lactic acidosis in acute asthma

The following variables were measured in each patient immediately before starting treatment and at 30 minute intervals until 2 hours after presentation: FEV₁, respiratory rate, heart rate, accessory muscle use, dyspnoea, wheezing, and SpO₂. Additionally, pH, PaO₂, PaCO₂, HCO₃⁻, K⁺, Na⁺, Cl⁻, and lactate levels, and arterial mean pressure were obtained at baseline and at the end of protocol. FEV₁ was measured using a Vitalograph Compact spirometer (Vitalograph Ltd., Maids Moreton House, Buckingham, UK). Three successive maximal expiratory curves were recorded at each assessment, and the highest value was selected, according to the criteria of the American Thoracic Society. Heart rate was measured from continuous electrocardiogram. Arterial oxygen saturation was monitored by pulse oximetry with a finger oximeter (Nellcor N-180 Pulse oximeter; Hayward, CA, USA). Accessory muscle use was defined as visible retraction of the sternocleidomastoid muscles. Dyspnoea was defined as the patient’s own assessment of breathlessness. PaO₂, PaCO₂, and pH were measured with a blood gas analyser using routine techniques (ABL 500 system; Radiometer America Westlake, OH, USA). Plasma Na⁺, K⁺, and Cl⁻ were assayed by flame photometry (Radiometer EMI 100). Finally, arterial lactate concentrations (normal value ≤ 2.2 mmol/l) were performed using a blood gas analyser (Rapid lab 864; Chiron Diagnostics, Bayer; Leverkusen, Germany). To determine duration of onset of present attack, patients were asked to indicate the onset of wheeze, cough, shortness of breath, or some combination of these symptoms, and additionally, any decline in peak flow, if available, was noted.

Statistical analysis

Means (SD) were calculated for continuous variables. The 95% confidence intervals (CI) were obtained with standard formulas. Changes in FEV₁ were evaluated using repeated measures analysis of variance. When the F value indicated significant differences among group means, post hoc pairwise multiple comparisons were performed using the Newman-Keuls test. Baseline and final data were compared by the Mann-Whitney U test for independent samples, or Wilcoxon matched pairs signed rank test for related samples. The χ² test with Yates’ correction or Fisher’s exact test was used for categorical variables. All data were analysed with the SPSS for Window software package (version 11.0; SPSS Inc., Chicago, IL, USA). A p value <0.05 using a two tailed test was taken as significant for all statistical tests.

RESULTS

In total, 20 consecutive adults with an acute exacerbation of asthma were recruited for entry into this study. Two patients were excluded because they were unable to perform spirometry, thus 18 adults completed the study (mean age 42.9 (2.7) years). Baseline characteristics of patients are presented in table 1. They had severe airway obstruction (mean FEV₁ 32.2 (10.9)% of predicted), moderate hypoxemia (mean PaO₂ 76.6 (11.7) mmHg), hypocarbia (mean PaCO₂ 35.9 (3.3) mmHg), and normal pH (7.41 (0.02). No intubated or ventilated patients were included in the study. Although all patients had received beta agonists 24 hours before their arrival in the ED, plasma lactate levels were within normal values (< 2.2 mmol/l) in all patients.

The relationship between cumulative doses of albuterol and change in FEV₁, heart rate, and SpO₂ were analysed. Overall, patients demonstrated improved lung function and gas exchange, and showed an increase in heart rate as a response to β₂ agonist treatment. There were dose related significant increases in the three variables over baseline values (p < 0.001). At final disposition, the mean values of FEV₁, heart rate, and SpO₂ were 71.3 (22.2)% 101.6 (8.2) beats/min, and 97.4 (1.5) respectively.

At the end of treatment, the mean plasma lactate level (2.94 (2.1) mmol/l) was significantly higher (p = 0.001) than

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Demographic and baseline characteristics of patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Variables</td>
<td>Results</td>
</tr>
<tr>
<td>Men/women</td>
<td>9/9 (50/50)*</td>
</tr>
<tr>
<td>Age, years</td>
<td>42.9 (2.7)</td>
</tr>
<tr>
<td>Duration of attack prior to ED presentation, hours</td>
<td>39.2 (39.0)</td>
</tr>
<tr>
<td>Heart rate, beats/min</td>
<td>94.6 (5.6)</td>
</tr>
<tr>
<td>Blood pressure, mm Hg</td>
<td>127.6 (16.6)</td>
</tr>
<tr>
<td>Systolic</td>
<td>75.5 (12.8)</td>
</tr>
<tr>
<td>Diastolic</td>
<td>22.4 (4.2)</td>
</tr>
<tr>
<td>Respiratory rate, breaths/min</td>
<td>0.9 (0.3)</td>
</tr>
<tr>
<td>FEV₁, % predicted</td>
<td>32.2 (10.9)</td>
</tr>
<tr>
<td>SpO₂</td>
<td>94.7 (2.7)</td>
</tr>
<tr>
<td>pH</td>
<td>7.4 (0.0)</td>
</tr>
<tr>
<td>PaO₂, mm Hg</td>
<td>76.6 (11.7)</td>
</tr>
<tr>
<td>PaCO₂, mm Hg</td>
<td>35.9 (3.3)</td>
</tr>
<tr>
<td>HCO₃⁻, mmol/l</td>
<td>22.5 (1.3)</td>
</tr>
<tr>
<td>Na⁺, mmol/l</td>
<td>138.5 (2.5)</td>
</tr>
<tr>
<td>K⁺, mmol/l</td>
<td>3.8 (0.2)</td>
</tr>
<tr>
<td>Cl⁻, mmol/l</td>
<td>101.6 (5.0)</td>
</tr>
<tr>
<td>Lactate, mmol/l</td>
<td>1.1 (0.4)</td>
</tr>
</tbody>
</table>

*p = 0.001. All other results in this column are mean (SD).

Figure 1 Baseline and posttreatment lactate levels. Circles represent individual values and squares mean (SD) values. The mean serum lactate level at the end of treatment was significantly higher (p = 0.001) than baseline.

www.emjonline.com
baseline (fig 1). After 2 hours of treatment, nine patients (50%) showed lactate levels ≥2.5 mmol/l (four patients presented values >4 mmol/l). Final lactate concentration was significantly correlated with pretreatment heart rate (p = 0.58, 95% CI 0.15 to 0.82, p = 0.01) and inversely correlated with baseline serum potassium (p = -0.48, 95% CI -0.78 to -0.09, p = 0.04). When patients were classified according to final lactate concentration (patients with low lactate concentrations (<4 mmol/l) versus patients with very high lactate concentrations (≥4 mmol/l)), significant relationships were found. Patients with final high lactate concentrations had a shorter duration of attack prior to ED presentation (three patients presented a duration of attack <3 hours; p = 0.01), a higher pretreatment heart rate (p = 0.005), a lower pretreatment SpO2 (p = 0.03), a lower pretreatment PO2 (p = 0.009), a higher pretreatment PCO2, and a lower pretreatment serum potassium (p = 0.005). In addition, there was a non-significant lower pretreatment pulmonary function (FEV1). In contrast, there were no differences between the two subgroups in baseline lactate level (table 2). FEV1 responses at each time point during treatment for the two subgroups are shown in fig 2. There were no significant differences in the airway response. At final disposition (120 minutes), the mean percentage predicted FEV1 was 70.9 (23.0%) in the low lactate level subgroup, and 73.0 (22.6%), in the high lactate level subgroup (mean difference -2.1, 95% CI -29.6 to 25.4, p = 0.7).

**DISCUSSION**

Although lactic acidosis is a common metabolic disturbance in acute asthma, its pathogenesis remains controversial. In type A lactic acidosis, the impaired oxygen delivery or consumption leads to increased anaerobic glycolysis with terminal conversion of the resulting pyruvate to lactate instead of through the Krebs cycle of aerobic metabolism. Thus, in sepsis and shock, lactic acidosis is used as a marker of disease severity.18 19 On the other hand, type B lactic acidosis is associated with an altered cellular metabolism (in absence of hypoperfusion or hypoxia), with either decreased lactate metabolism or increased flux of pyruvate to lactate rather than into the Krebs cycle.20 Conditions associated with type B lactic acidosis include inborn errors of metabolism (pyruvate dehydrogenase deficiency), systemic disorders (liver failure), and adverse effects of medications (ethanol, metformin, and corticoids).21 It has also been postulated that endogenous (distress) or exogenous (drugs) adrenergic stimulation may be associated with increased conversion of pyruvate to lactate.22 Stimulation of β-adrenergic receptors leads to a variety of metabolic effects, including increases in fatty acids and plasma glucose concentrations.23 glycolysis,
gluconeogenesis, and lypolysis.\textsuperscript{20} In particular, epinephrine (adrenaline) has been associated with increases in plasma lactate concentrations in normal volunteers\textsuperscript{22} and after cardiac surgery.\textsuperscript{23–25} Recently, several case reports have been published that linked lactic acidosis to inhaled \( \beta_2 \) agonist therapy in patients with acute asthma in absence of hypoxia or shock.\textsuperscript{6,7}

The findings of our study are in accordance with previous reports. We found that hyperlactataemia can develop during the first hours of treatment even in the absence of severe bronchial obstruction. In our group, 50\% patients showed a rapid (2 hours) increase in lactate levels after the use of high doses of inhaled beta agonists, and four presented final very high levels (>4 mmol/l). However, patients did not become acidotic from their lactate elevations, and \( P_CO_2 \) measurements also showed that these patients did not have respiratory alkalosis as compensation for acidosis. Our patients presented no evidence of liver or renal dysfunction. In addition, they had normal mean arterial pressures, and experienced no clinical or laboratory signs of hyperperfusion. The pretreatment degree of hypoxia was also not severe, and the study did not consider the relationship between albuterol doses and lactate levels. However, an increase in albuterol dose from 400 \( \mu \)g every 10 minutes produces a slightly better therapeutic response but with greater side effects.\textsuperscript{21} (c) Although all patients received beta agonists prior to ED presentation, there was no quantification of the doses received to assist in measuring any previous hyperadrenergic state.

**Authors’ affiliations**

G J Rodrigo, Departamento de Emergencia, Hospital Central de las Fuerzas Armadas, Montevideo, Uruguay

C Rodrigo, Unidad de Cuidado Intensivo, Asociación Española 1 de Socorros Mutuos, Montevideo, Uruguay

Competing interests: none declared

**REFERENCES**


Clinical Evidence—Call for contributors

*Clinical Evidence* is a regularly updated evidence-based journal available worldwide both as a paper version and on the internet. *Clinical Evidence* needs to recruit a number of new contributors. Contributors are healthcare professionals or epidemiologists with experience in evidence-based medicine and the ability to write in a concise and structured way.

**Areas for which we are currently seeking authors:**
- Child health: nocturnal enuresis
- Eye disorders: bacterial conjunctivitis
- Male health: prostate cancer (metastatic)
- Women’s health: pre-menstrual syndrome; pyelonephritis in non-pregnant women

However, we are always looking for others, so do not let this list discourage you.

**Being a contributor involves:**
- Selecting from a validated, screened search (performed by in-house Information Specialists) epidemiologically sound studies for inclusion.
- Documenting your decisions about which studies to include on an inclusion and exclusion form, which we keep on file.
- Writing the text to a highly structured template (about 1500–3000 words), using evidence from the final studies chosen, within 8–10 weeks of receiving the literature search.
- Working with *Clinical Evidence* editors to ensure that the final text meets epidemiological and style standards.
- Updating the text every six months using any new, sound evidence that becomes available. The *Clinical Evidence* in-house team will conduct the searches for contributors; your task is simply to filter out high quality studies and incorporate them in the existing text.
- To expand the topic to include a new question about once every 12–18 months.

If you would like to become a contributor for *Clinical Evidence* or require more information about what this involves please send your contact details and a copy of your CV, clearly stating the clinical area you are interested in, to Klara Brunnhuber (kbrunnhuber@bmjgroup.com).

Call for peer reviewers

*Clinical Evidence* also needs to recruit a number of new peer reviewers specifically with an interest in the clinical areas stated above, and also others related to general practice. Peer reviewers are healthcare professionals or epidemiologists with experience in evidence-based medicine. As a peer reviewer you would be asked for your views on the clinical relevance, validity, and accessibility of specific topics within the journal, and their usefulness to the intended audience (international generalists and healthcare professionals, possibly with limited statistical knowledge). Topics are usually 1500–3000 words in length and we would ask you to review between 2–5 topics per year. The peer review process takes place throughout the year, and our turnaround time for each review is ideally 10–14 days.

If you are interested in becoming a peer reviewer for *Clinical Evidence*, please complete the peer review questionnaire at www.clinicalevidence.com or contact Klara Brunnhuber (kbrunnhuber@bmjgroup.com).